The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

A major trial is coming to Greater Manchester to see how a new drug can tackle obesity. The ‘five-year real-world evidence study’ will be run by Health Innovation Manchester and pharmaceutical giant ...

Editorial: The chancellor spoke of capping corporation tax to give a much-needed boost to British businesses, as the PM ...

Prime minister Sir Keir Starmer has refused to rule out increasing employers’ national insurance contributions in the ...

University of Iowa freshman Naomi Simon finished third at 76 kg at the U20 World Championships. Simon defeated Chisato Yoshida of Japan in the bronze medal match via decision. 9-0.

Arch Capital Group Ltd. today announced that Nicolas Papadopoulo has been named Chief Executive Officer and is joining the Board of Directors effective immediately. Papadopoulo has held his current ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.